Intelligent Bio Solutions Advances Non-Invasive Drug Testing Technology for U.S. Market
Intelligent Bio Solutions is progressing toward FDA clearance for a groundbreaking fingerprint-based drug screening system with 94.1% accuracy, positioning the company for potential expansion across safety-critical industries in the United States.
Intelligent Bio Solutions is preparing for a significant market entry in the United States with its innovative Intelligent Fingerprinting Drug Screening System. The medical technology company has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration, seeking clearance for its opiate test system.
The non-invasive device, which detects recent drug use through fingerprint sweat analysis, has demonstrated 94.1% accuracy in identifying opiates. This technology offers a rapid, portable testing solution that can be integrated into various safety-critical work environments.
Currently operating in 24 countries with over 450 commercial accounts, the company has already established a global presence across diverse industries including logistics, mining, retail, and marine operations. The upcoming U.S. launch, anticipated in 2025, represents a potentially transformative expansion for the company's drug screening technology.
The FDA's classification of the system as a Class II medical device underscores its potential clinical and workplace safety applications. By providing a quick, non-invasive method of drug screening, Intelligent Bio Solutions could revolutionize how organizations approach workplace drug testing, offering a more convenient and less intrusive alternative to traditional testing methods.
As the company continues to expand its distributor network, the potential market impact extends beyond immediate technological innovation, potentially setting new standards for rapid, accurate drug screening across multiple sectors.